Macquarie Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Macquarie Group’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,285	Closed	-$175K	–	1971
2024 Q2	$175K	Buy	+4,285	New	+$178K	﹤0.01%	1565
2022 Q3	–	Sell	-665	Closed	-$19.8K	–	2223
2022 Q2	$18K	Hold	665	–	–	﹤0.01%	2345
2022 Q1	$23	Hold	665	–	–	﹤0.01%	2361
2021 Q4	$22K	Buy	+665	New	+$23.5K	﹤0.01%	2379

Other funds holding CERE

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Macquarie Group's CERE Position: Q3 2024 in Review

Macquarie Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 4,285 shares — an estimated $175K sold.

Macquarie Group first reported a position in CERE in Q4 2021 and held it in 4 quarters. The position peaked at $175K in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

Macquarie Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 4,285 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $175K.
Macquarie Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Macquarie Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $175K in Q2 2024.
2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.